What is the 13F Pro Quality Score for ACXP?

13F Pro ranks Acurx Pharmaceuticals, Inc. (ACXP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACXP's current score at https://13fpro.ai/research/ACXP (free sign-up required for the full ranking).

Where does 13F Pro source ACXP data?

All Acurx Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Acurx Pharmaceuticals, Inc. files with the SEC under CIK 1736243. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACXP in?

Acurx Pharmaceuticals, Inc. (ACXP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ACXP research updated on 13F Pro?

ACXP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Acurx Pharmaceuticals, Inc.(ACXP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1736243 ACXP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ACXP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Acurx Pharmaceuticals, Inc. (ACXP), a Healthcare sector company. ACXP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Acurx Pharmaceuticals, Inc. reports net income of $-1.7M, free cash flow of $-1.4M. Top institutional holders of ACXP by reported 13-F value include JANE STREET GROUP,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. ACXP trades on the Nasdaq exchange and files with the SEC under CIK 1736243. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acurx Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.7M

Free Cash Flow

Q1 2026

$-1.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+3.3% YoY

$-14.1MFY 2024

FY20 $-4.6MFY21 $-12.7MFY23 $-14.6MFY24 $-14.1M

Operating Income

$-14.1MFY 2024

FY20 —FY21 —FY23 —FY24 $-14.1M

EPS (Diluted)

-1417.4% YoY

$-17.45FY 2024

FY20 $-0.74FY21 $-1.49FY23 $-1.15FY24 $-17.45

Total Assets

-50.0% YoY

$3.9MFY 2024

FY20 $3.2MFY21 $13.3MFY23 $7.7MFY24 $3.9M

Op. Cash Flow

-5.9% YoY

$-10.4MFY 2024

FY20 $-3.4MFY21 $-5.0MFY23 $-9.8MFY24 $-10.4M

Metric	FY 2024	FY 2023	FY 2021	FY 2020
Net Income	$-14.1M +3.3%	$-14.6M -14.4%	$-12.7M -177.1%	$-4.6M
Operating Income	$-14.1M	—	—	—
EPS (Diluted)	$-17.45 -1417.4%	$-1.15 +22.8%	$-1.49 -101.4%	$-0.74
Total Assets	$3.9M -50.0%	$7.7M -41.8%	$13.3M +311.1%	$3.2M
Operating Cash Flow	$-10.4M -5.9%	$-9.8M -95.5%	$-5.0M -49.6%	$-3.4M

AI Insight: ACXP Financial Trends

ACXP remains pre-revenue with persistent net losses, but cash burn is narrowing and equity has more than doubled since Q4 2024.

• Net loss improved from -$4M in Q2 2024 to -$2M by Q1 2025 and has held steady since.

• Operating cash outflow narrowed from -$3M in Q2 2024 to -$1M in both Q4 2025 and Q1 2026.

• Equity grew from $1M in Q4 2024 to $7M in Q1 2026, suggesting capital raises are supporting the balance sheet.

⚠ Zero revenue across all eight quarters — the company is entirely dependent on external financing to fund operations.

⚠ Equity expansion likely reflects dilutive share issuances; burn rate versus cash runway is critical to monitor.

AI Insight: ACXP Ratio Trends

Extremely sparse data limits analysis; only ROE and ROA are available, both deeply negative but showing slight sequential improvement.

• ROE improved from -119.8% in Q4 2025 to -95.9% in Q1 2026, a 23.9pp sequential gain.

• ROA improved from -82.1% in Q4 2025 to -70.5% in Q1 2026, a 11.6pp sequential improvement.

• TTM ROE of -106.9% and ROA of -78.6% confirm sustained deep losses with no profitability in sight.

⚠ OpMargin, NPM, ROIC, and D/E remain unavailable across all periods — insufficient data to assess operational efficiency or leverage.

⚠ ROIC of -97.9% in Q1 2026 signals capital destruction; sustainability of operations depends on external funding.

Get alerted when ACXP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Acurx Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACXP

JANE STREET GROUP, LLC
$202.7K54,642 sh
VANGUARD CAPITAL MANAGEMENT LLC
$115.4K31,099 sh
GEODE CAPITAL MANAGEMENT, LLC
$92.1K24,819 sh
VANGUARD FIDUCIARY TRUST CO
$60.1K16,205 sh
Prospect Financial Services LLC
$51.1K13,785 sh
MORGAN STANLEY
$24.1K6,500 sh
UBS Group AG
$23.4K6,312 sh
WELLS FARGO & COMPANY/MN
$8.5K2,300 sh
Westside Investment Management, Inc.
$6.1K1,650 sh
NBC SECURITIES, INC.
$5.6K1,500 sh

Fund	Value	Shares
JANE STREET GROUP, LLC	$202.7K	54,642
VANGUARD CAPITAL MANAGEMENT LLC	$115.4K	31,099
GEODE CAPITAL MANAGEMENT, LLC	$92.1K	24,819
VANGUARD FIDUCIARY TRUST CO	$60.1K	16,205
Prospect Financial Services LLC	$51.1K	13,785
MORGAN STANLEY	$24.1K	6,500
UBS Group AG	$23.4K	6,312
WELLS FARGO & COMPANY/MN	$8.5K	2,300
Westside Investment Management, Inc.	$6.1K	1,650
NBC SECURITIES, INC.	$5.6K	1,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACXP on your watchlist

Track score changes the day Acurx Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACXP a good stock to buy?

13F Pro's AI-powered analysis of Acurx Pharmaceuticals, Inc. (ACXP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACXP are available on the ACXP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ACXP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACXP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Acurx Pharmaceuticals, Inc.'s investment landscape.